

Paul A Monach

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9544599/publications.pdf>

Version: 2024-02-01

116
papers

8,975
citations

61984

43
h-index

42399

92
g-index

119
all docs

119
docs citations

119
times ranked

9211
citing authors

#	ARTICLE	IF	CITATIONS
1	Coronavirus disease 2019 (COVID-19) hospitalization metrics that do not account for disease severity underestimate protection provided by severe acute respiratory coronavirus virus 2 (SARS-CoV-2) vaccination and boosting: A retrospective cohort study. <i>Infection Control and Hospital Epidemiology</i> , 2023, 44, 149-151.	1.8	4
2	Hypothyroidism in vasculitis. <i>Rheumatology</i> , 2022, 61, 2942-2950.	1.9	2
3	Serum Biomarkers of Disease Activity in Longitudinal Assessment of Patients with ANCA-Associated Vasculitis. <i>ACR Open Rheumatology</i> , 2022, 4, 168-176.	2.1	6
4	Impact of prior SARS-CoV-2 infection on incidence of hospitalization and adverse events following mRNA SARS-CoV-2 vaccination: A nationwide, retrospective cohort study. <i>Vaccine</i> , 2022, 40, 1082-1089.	3.8	9
5	The COVID-19 hospitalization metric in the pre- and postvaccination eras as a measure of pandemic severity: A retrospective, nationwide cohort study. <i>Infection Control and Hospital Epidemiology</i> , 2022, 43, 1767-1772.	1.8	25
6	Self-Reported Data and Physician-Reported Data in Patients With Eosinophilic Granulomatosis With Polyangiitis: Comparative Analysis. <i>Interactive Journal of Medical Research</i> , 2022, 11, e27273.	1.4	2
7	Neutrophil activation in patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis and large-vessel vasculitis. <i>Arthritis Research and Therapy</i> , 2022, 24, .	3.5	12
8	Sequence-Based Screening of Patients With Idiopathic Polyarteritis Nodosa, Granulomatosis With Polyangiitis, and Microscopic Polyangiitis for Deleterious Genetic Variants in <i>ADA2</i> . <i>Arthritis and Rheumatology</i> , 2021, 73, 512-519.	5.6	34
9	Clinically isolated aortitis: imaging features and clinical outcomes: comparison with giant cell arteritis and giant cell aortitis. <i>International Journal of Cardiovascular Imaging</i> , 2021, 37, 1433-1443.	1.5	6
10	Identification of susceptibility loci for Takayasu arteritis through a large multi-ancestral genome-wide association study. <i>American Journal of Human Genetics</i> , 2021, 108, 84-99.	6.2	26
11	Clinical Manifestations and Long-Term Outcomes of Eosinophilic Granulomatosis With Polyangiitis in North America. <i>ACR Open Rheumatology</i> , 2021, 3, 404-412.	2.1	21
12	The neutrotime transcriptional signature defines a single continuum of neutrophils across biological compartments. <i>Nature Communications</i> , 2021, 12, 2856.	12.8	149
13	Aspirin Dosing in Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2021, 385, 764-765.	27.0	1
14	Reconsidering "minimal risk" to expand the repertoire of trials with waiver of informed consent for research. <i>BMJ Open</i> , 2021, 11, e048534.	1.9	5
15	Implementation of documented and written informed consent for clinical trials of communicable diseases: Lessons learned, barriers, solutions, future directions identified during the conduct of a COVID-19 clinical trial. <i>Contemporary Clinical Trials Communications</i> , 2021, 23, 100804.	1.1	9
16	Identification of Acute Giant Cell Arteritis in Real-World Data Using Administrative Claims-Based Algorithms. <i>ACR Open Rheumatology</i> , 2021, 3, 72-78.	2.1	4
17	Circulating autoreactive proteinase 3+ B cells and tolerance checkpoints in ANCA-associated vasculitis. <i>JCI Insight</i> , 2021, 6, .	5.0	7
18	Efficacy of leflunomide in the treatment of vasculitis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 129, 114-118.	0.8	3

#	ARTICLE	IF	CITATIONS
19	Urinary soluble CD163 and monocyte chemoattractant protein-1 in the identification of subtle renal flare in anti-neutrophil cytoplasmic antibody-associated vasculitis. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 283-291.	0.7	40
20	Derivation of an angiographically based classification system in Takayasu's arteritis: an observational study from India and North America. <i>Rheumatology</i> , 2020, 59, 1118-1127.	1.9	33
21	Evaluation of Potential Serum Biomarkers of Disease Activity in Diverse Forms of Vasculitis. <i>Journal of Rheumatology</i> , 2020, 47, 1001-1010.	2.0	20
22	Patterns of Arterial Disease in Takayasu Arteritis and Giant Cell Arteritis. <i>Arthritis Care and Research</i> , 2020, 72, 1615-1624.	3.4	77
23	Pragmatic, adaptive clinical trials: Is 2020 the dawning of a new age?. <i>Contemporary Clinical Trials Communications</i> , 2020, 19, 100614.	1.1	9
24	Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3 in ANCA-Associated Vasculitis. <i>Frontiers in Immunology</i> , 2020, 11, 2053.	4.8	12
25	Long-Term Safety of Rituximab in Granulomatosis with Polyangiitis or Microscopic Polyangiitis. <i>Arthritis Care and Research</i> , 2020, 73, 1372-1378.	3.4	11
26	ImmGen at 15. <i>Nature Immunology</i> , 2020, 21, 700-703.	14.5	55
27	Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1243-1249.	0.9	93
28	Patterns of clinical presentation in Takayasu's arteritis. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 576-581.	3.4	25
29	Bringing New Meaning to the Term "Adaptive Trial": Challenges of Conducting Clinical Research During the Coronavirus Disease 2019 Pandemic and Implications for Implementation Science. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa490.	0.9	10
30	Arterial lesions in giant cell arteritis: A longitudinal study. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 707-713.	3.4	43
31	The association of serum interleukin-6 levels with clinical outcomes in antineutrophil cytoplasmic antibody-associated vasculitis. <i>Journal of Autoimmunity</i> , 2019, 105, 102302.	6.5	24
32	Subglottic stenosis and endobronchial disease in granulomatosis with polyangiitis. <i>Rheumatology</i> , 2019, 58, 2203-2211.	1.9	37
33	Association of Pulmonary Hemorrhage, Positive Proteinase 3, and Urinary Red Blood Cell Casts With Venous Thromboembolism in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2019, 71, 1888-1893.	5.6	25
34	Disease Activity, Antineutrophil Cytoplasmic Antibody Type, and Lipid Levels in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2019, 71, 1879-1887.	5.6	23
35	Feasibility and Construct Validation of the Patient Reported Outcomes Measurement Information System in Systemic Vasculitis. <i>Journal of Rheumatology</i> , 2019, 46, 928-934.	2.0	6
36	SAT0012â€¦DETECTION OF CIRCULATING PR3-SPECIFIC B CELLS IN PATIENTS WITH ACTIVE ANCA-ASSOCIATED VASCULITIS. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
37	Disease heterogeneity in antineutrophil cytoplasmic antibody-associated vasculitis: implications for therapeutic approaches. <i>Lancet Rheumatology</i> , The, 2019, 1, e247-e256.	3.9	4
38	Serum cytokine and chemokine levels in patients with eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome, or eosinophilic asthma. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 117, 40-44.	0.8	7
39	Evaluation of damage in giant cell arteritis. <i>Rheumatology</i> , 2018, 57, 322-328.	1.9	28
40	Brief Report: Circulating Cytokine Profiles and Antineutrophil Cytoplasmic Antibody Specificity in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2018, 70, 1114-1121.	5.6	49
41	Pharmacokinetics of rituximab and clinical outcomes in patients with anti-neutrophil cytoplasmic antibody associated vasculitis. <i>Rheumatology</i> , 2018, 57, 639-650.	1.9	20
42	The Utility of Urinalysis in Determining the Risk of Renal Relapse in ANCA-Associated Vasculitis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 251-257.	4.5	50
43	Serum biomarkers of glucocorticoid response and safety in anti-neutrophil cytoplasmic antibody-associated vasculitis and juvenile dermatomyositis. <i>Steroids</i> , 2018, 140, 159-166.	1.8	24
44	Serum periostin as a biomarker in eosinophilic granulomatosis with polyangiitis. <i>PLoS ONE</i> , 2018, 13, e0205768.	2.5	6
45	A Randomized, Double-blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Takayasu Arteritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 846-853.	5.6	131
46	Case 6-2017. <i>New England Journal of Medicine</i> , 2017, 376, 775-786.	27.0	9
47	Assessing Performance of Internal Medicine Residents. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 1276.	7.4	0
48	Identification of Functional and Expression Polymorphisms Associated With Risk for Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2017, 69, 1054-1066.	5.6	130
49	A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. <i>American Journal of Human Genetics</i> , 2017, 100, 64-74.	6.2	78
50	Interstitial Immunostaining and Renal Outcomes in Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis. <i>American Journal of Nephrology</i> , 2017, 46, 231-238.	3.1	15
51	The Pharmacogenomic Association of Fc γ 3 Receptors and Cytochrome P450 Enzymes With Response to Rituximab or Cyclophosphamide Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2017, 69, 169-175.	5.6	21
52	Effect of Disease Activity, Glucocorticoid Exposure, and Rituximab on Body Composition During Induction Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis Care and Research</i> , 2017, 69, 1004-1010.	3.4	11
53	Association of Serum Calprotectin (S100A8/A9) Level With Disease Relapse in Proteinase 3-Associated Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2017, 69, 185-193.	5.6	45
54	Anti-neutrophil Cytoplasmic Antibody-Associated Vasculitis. , 2017, , 1541-1558.e4.		4

#	ARTICLE	IF	CITATIONS
55	Megakaryocytes compensate for Kit insufficiency in murine arthritis. <i>Journal of Clinical Investigation</i> , 2017, 127, 1714-1724.	8.2	32
56	Experience With Direct-to-Patient Recruitment for Enrollment Into a Clinical Trial in a Rare Disease: A Web-Based Study. <i>Journal of Medical Internet Research</i> , 2017, 19, e50.	4.3	24
57	IgA antibodies to myeloperoxidase in patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss). <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 103, 98-101.	0.8	3
58	Using Mass Spectrometry to Quantify Rituximab and Perform Individualized Immunoglobulin Phenotyping in ANCA-Associated Vasculitis. <i>Analytical Chemistry</i> , 2016, 88, 6317-6325.	6.5	24
59	The Birmingham Vasculitis Activity Score as a Measure of Disease Activity in Patients with Giant Cell Arteritis. <i>Journal of Rheumatology</i> , 2016, 43, 1078-1084.	2.0	37
60	Myeloperoxidase-Positive and ANCA-Negative Patients With Granulomatosis With Polyangiitis (Wegener's): Distinct Patient Subsets. <i>Arthritis and Rheumatology</i> , 2016, 68, 2945-2952.	5.6	75
61	Factors Determining the Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3. <i>Arthritis and Rheumatology</i> , 2016, 68, 1700-1710.	5.6	132
62	Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1166-1169.	0.9	196
63	Vasculitis in patients with inflammatory bowel diseases: A study of 32 patients and systematic review of the literature. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 45, 475-482.	3.4	109
64	Promotion of Inflammatory Arthritis by Interferon Regulatory Factor 5 in a Mouse Model. <i>Arthritis and Rheumatology</i> , 2015, 67, 3146-3157.	5.6	36
65	Serum Biomarkers in Patients with Relapsing Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss). <i>PLoS ONE</i> , 2015, 10, e0121737.	2.5	35
66	Disease Relapses among Patients with Giant Cell Arteritis: A Prospective, Longitudinal Cohort Study. <i>Journal of Rheumatology</i> , 2015, 42, 1213-1217.	2.0	129
67	Neutrophil-Related Gene Expression and Low-Density Granulocytes Associated With Disease Activity and Response to Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2015, 67, 1922-1932.	5.6	116
68	Cardiac Involvement in Granulomatosis with Polyangiitis. <i>Journal of Rheumatology</i> , 2015, 42, 1209-1212.	2.0	87
69	A Large-Scale Genetic Analysis Reveals a Strong Contribution of the HLA Class II Region to Giant Cell Arteritis Susceptibility. <i>American Journal of Human Genetics</i> , 2015, 96, 565-580.	6.2	144
70	Primary Angiitis of the Central Nervous System in Adults and Children. <i>Rheumatic Disease Clinics of North America</i> , 2015, 41, 47-62.	1.9	22
71	Value of commonly measured laboratory tests as biomarkers of disease activity and predictors of relapse in eosinophilic granulomatosis with polyangiitis. <i>Rheumatology</i> , 2015, 54, 1351-1359.	1.9	52
72	Peripheral CD5+ B Cells in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2015, 67, 535-544.	5.6	25

#	ARTICLE	IF	CITATIONS
73	The rheumatoid joint. , 2015, , 768-784.		1
74	Gene Expression during the Generation and Activation of Mouse Neutrophils: Implication of Novel Functional and Regulatory Pathways. PLoS ONE, 2014, 9, e108553.	2.5	83
75	Biomarkers in vasculitis. Current Opinion in Rheumatology, 2014, 26, 24-30.	4.3	63
76	The Tumor Microenvironment Shapes Lineage, Transcriptional, and Functional Diversity of Infiltrating Myeloid Cells. Cancer Immunology Research, 2014, 2, 655-667.	3.4	63
77	Efficacy of Remission-Induction Regimens for ANCA-Associated Vasculitis. New England Journal of Medicine, 2013, 369, 417-427.	27.0	611
78	Identification of Multiple Genetic Susceptibility Loci in Takayasu Arteritis. American Journal of Human Genetics, 2013, 93, 298-305.	6.2	143
79	Serum proteins reflecting inflammation, injury and repair as biomarkers of disease activity in ANCA-associated vasculitis. Annals of the Rheumatic Diseases, 2013, 72, 1342-1350.	0.9	109
80	L25. Medical treatment of subglottic stenosis in granulomatosis with polyangiitis (Wegener's). Presse Medicale, 2013, 42, 575-576.	1.9	6
81	The transcriptional landscape of $\hat{I}\pm\hat{I}^2$ T cell differentiation. Nature Immunology, 2013, 14, 619-632.	14.5	256
82	Identification of transcriptional regulators in the mouse immune system. Nature Immunology, 2013, 14, 633-643.	14.5	179
83	IgG4-related Disease: 2013 Update. Current Treatment Options in Cardiovascular Medicine, 2013, 15, 214-223.	0.9	11
84	Association of Granulomatosis With Polyangiitis (Wegener's) With <i>HLA</i> â€“DPB1*04 and <i>SEMA6A</i> Gene Variants: Evidence From Genome-wide Analysis. Arthritis and Rheumatism, 2013, 65, 2457-2468.	6.7	138
85	New Features of Disease After Diagnosis in 6 Forms of Systemic Vasculitis. Journal of Rheumatology, 2013, 40, 1905-1912.	2.0	40
86	ANCA-associated Vasculitis: A Prothrombotic State Even in Remission?. Journal of Rheumatology, 2013, 40, 1935-1937.	2.0	5
87	Urinary Biomarkers in Relapsing Antineutrophil Cytoplasmic Antibody-associated Vasculitis. Journal of Rheumatology, 2013, 40, 674-683.	2.0	39
88	Distribution of arterial lesions in Takayasu's arteritis and giant cell arteritis. Annals of the Rheumatic Diseases, 2012, 71, 1329-1334.	0.9	218
89	Repeating tests: different roles in research studies and clinical medicine. Biomarkers in Medicine, 2012, 6, 691-703.	1.4	14
90	Association of Vascular Physical Examination Findings and Arteriographic Lesions in Large Vessel Vasculitis. Journal of Rheumatology, 2012, 39, 303-309.	2.0	51

#	ARTICLE	IF	CITATIONS
91	Meta-analysis of genetic polymorphisms in granulomatosis with polyangiitis (Wegener's) reveals shared susceptibility loci with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2012, 64, 3463-3471.	6.7	33
92	Circulating Angiopoietin-2 as a Biomarker in ANCA-Associated Vasculitis. <i>PLoS ONE</i> , 2012, 7, e30197.	2.5	16
93	Assessment of health-related quality of life as an outcome measure in granulomatosis with polyangiitis (Wegener's). <i>Arthritis Care and Research</i> , 2012, 64, 273-279.	3.4	49
94	Antineutrophil Cytoplasmic Antibodies, Autoimmune Neutropenia, and Vasculitis. <i>Seminars in Arthritis and Rheumatism</i> , 2011, 41, 424-433.	3.4	19
95	Circulating markers of vascular injury and angiogenesis in antineutrophil cytoplasmic antibody-associated vasculitis. <i>Arthritis and Rheumatism</i> , 2011, 63, 3988-3997.	6.7	59
96	IgA and IgG antineutrophil cytoplasmic antibody engagement of Fc receptor genetic variants influences granulomatosis with polyangiitis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 20736-20741.	7.1	74
97	Genetics of vasculitis. <i>Current Opinion in Rheumatology</i> , 2010, 22, 157-163.	4.3	45
98	Global versus organ-specific outcome measures in systemic lupus erythematosus: Comment on the articles by Furie et al, Nikpour et al, Wallace et al, Burgos et al, and Ramos-Casals et al. <i>Arthritis Care and Research</i> , 2010, 62, 580-581.	3.4	2
99	Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: A data-driven review. <i>Arthritis and Rheumatism</i> , 2010, 62, 9-21.	6.7	175
100	Neutrophils in a mouse model of autoantibody-mediated arthritis: Critical producers of Fc receptor β_3 , the receptor for C5a, and lymphocyte function-associated antigen 1. <i>Arthritis and Rheumatism</i> , 2010, 62, 753-764.	6.7	95
101	Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis. <i>New England Journal of Medicine</i> , 2010, 363, 221-232.	27.0	2,275
102	A broad screen for targets of immune complexes decorating arthritic joints highlights deposition of nucleosomes in rheumatoid arthritis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 15867-15872.	7.1	88
103	Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2009, 11, R76.	3.5	99
104	Thromboembolic disease in vasculitis. <i>Current Opinion in Rheumatology</i> , 2009, 21, 41-46.	4.3	73
105	The K/BxN Arthritis Model. <i>Current Protocols in Immunology</i> , 2008, 81, Unit 15.22.	3.6	153
106	Mast cells contribute to initiation of autoantibody-mediated arthritis via IL-1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 2325-2330.	7.1	168
107	Circulating C3 is necessary and sufficient for induction of autoantibody-mediated arthritis in a mouse model. <i>Arthritis and Rheumatism</i> , 2007, 56, 2968-2974.	6.7	21
108	Does knee malalignment predispose to osteoarthritis? Comment on the articles by Brouwer et al and Hunter et al and the editorial by Sharma. <i>Arthritis and Rheumatism</i> , 2007, 56, 3872-3872.	6.7	0

#	ARTICLE	IF	CITATIONS
109	The K/BxN Mouse Model of Inflammatory Arthritis. <i>Methods in Molecular Medicine</i> , 2007, 136, 269-282.	0.8	85
110	Characterization of relapses in adult idiopathic inflammatory myopathies. <i>Clinical Rheumatology</i> , 2006, 25, 476-481.	2.2	13
111	Antigen microarray profiling of autoantibodies in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2005, 52, 2645-2655.	6.7	256
112	The Role of Antibodies in Mouse Models of Rheumatoid Arthritis, and Relevance to Human Disease. <i>Advances in Immunology</i> , 2004, 82, 217-248.	2.2	100
113	Tuberculous osteomyelitis presenting as shoulder pain. <i>Journal of Rheumatology</i> , 2003, 30, 851-6.	2.0	21
114	Point Mutation in Essential Genes with Loss or Mutation of the Second Allele. <i>Journal of Experimental Medicine</i> , 2001, 194, 285-300.	8.5	40
115	Purification of tumor antigens recognized by CD4+ T lymphocytes. , 1996, , 1319-1326.		0
116	A unique tumor antigen produced by a single amino acid substitution. <i>Immunity</i> , 1995, 2, 45-59.	14.3	207